HAS split PNH into two tracks — ravulizumab first-line, iptacopan second-line only — and accès précoce set iptacopan's effective price months before the definitive negotiation closed.
France assesses medicines on two separate scales, not one. SMR (Service Médical Rendu), the actual-benefit rating that sets the statutory reimbursement rate, underpins ravulizumab's (Ultomiris) favourable opinion and its first-line positioning, which HAS grounded in every-eight-week dosing against eculizumab's every-two-week schedule. ASMR (Amélioration du Service Médical Rendu), the added-value rating that anchors CEPS price negotiation, applies to iptacopan (Fabhalta) — but the Commission de la Transparence gave it a favourable reimbursement opinion only for second-line use, in adults with symptomatic haemolytic anaemia after at least six months on a C5 complement inhibitor, and an unfavourable opinion for the other situations its marketing authorisation covers.
The sequencing matters as much as the rating. Iptacopan reached French patients before any definitive negotiation closed: HAS's Collège granted an accès précoce (AP1) authorisation by decision n°2024.0128/DC/SEM on 2 May 2024, ahead of the drug's EU-wide marketing authorisation, with rebates accruing on invoiced turnover from day one. HAS then published a separate economic opinion on 5 December 2024. A pricing strategy built on the US or UK label alone would miss both the second-line restriction and the early-access timeline that precedes it. The specific ASMR level granted and the negotiated CEPS prices for both agents could not be established in the public record available to us, and are deliberately omitted rather than estimated.
France PNH — ravulizumab's first-line track versus iptacopan's second-line-only track
| Agent | HAS position | Eligibility gate | Access route |
|---|---|---|---|
| Ultomiris (ravulizumab) | First-line | None within the reimbursed indication | Standard reimbursement pathway |
| Fabhalta (iptacopan) | Second-line only | Symptomatic haemolytic anaemia after ≥6 months on a C5 inhibitor | Accès précoce (AP1) from 2 May 2024, ahead of EU marketing authorisation |
Sources: HAS Commission de la Transparence, FABHALTA (iptacopan) — hémoglobinurie paroxystique nocturne; HAS Commission de la Transparence, ULTOMIRIS (ravulizumab); HAS, Décision n°2024.0128/DC/SEM du 2 mai 2024 (accès précoce); HAS, Avis économique FABHALTA (iptacopan), 5 décembre 2024.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- HAS's two-track SMR/ASMR assessment
- the ≥6-month prior anti-C5 criterion gating iptacopan's eligibility
- the every-eight-week dosing rationale behind ravulizumab's first-line position
Delivers
- The AP1 pre-authorisation mechanism and its 2 May 2024 decision date, ahead of EU marketing authorisation
- the rebate mechanism reconciling the indicative price to the definitive CEPS price
Delivers
- How CEPS anchors price to the ASMR rating, target population and European reference prices
- what a restricted indication does to negotiation leverage before a price is tabled
Custom model delivered in 72 hours.
Assess this reportWhat's inside
- Why HAS's two-track SMR/ASMR split, not a single technology appraisal, determines the negotiated price
- Pressure-tested against the ravulizumab first-line precedent before the rest of the model is built out
- How CEPS anchors price to the ASMR rating, target population size and European reference prices
- Where a restricted second-line indication changes the standard negotiation levers
- Why ravulizumab holds an unrestricted first-line position while iptacopan is reimbursed second-line only
- The ≥6-month prior anti-C5 eligibility gate
- Iptacopan's AP1 authorisation, 2 May 2024, ahead of EU marketing authorisation
- The rebate mechanism accruing on invoiced turnover before the definitive CEPS price lands
- Ravulizumab's weight-based vial pricing as the first-line comparator structure
- What the analogue class supports for a new entrant's defensible price
- The indicative accès précoce price, rebate layer, and definitive CEPS price decomposed line by line
- The reconciliation mechanism once the standard SMR/ASMR appraisal closes
- Sequencing recommendation across the accès précoce window and the definitive CEPS negotiation
- Conservative, base, and aggressive revenue scenarios tied to the eligible population
- The open pricing questions your team must close before the France launch price is locked
- Structured for an internal pricing committee session
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx pricing model is built from primary regulatory sources — HAS Commission de la Transparence opinions and CEPS pricing documentation, not secondary summaries. Findings are independently verified before inclusion.
PNH France pricing sources: HAS Commission de la Transparence records for iptacopan and ravulizumab, HAS's accès précoce decision n°2024.0128/DC/SEM of 2 May 2024, and HAS's economic opinion on iptacopan of 5 December 2024. Figures that could not be traced to a primary source — the ASMR level granted and the negotiated CEPS prices — are omitted rather than estimated.
- Iptacopan's second-line-only reimbursement opinion and its ≥6-month prior anti-C5 criterion verified against the live HAS Commission de la Transparence record
- Ravulizumab's first-line positioning verified against HAS Commission de la Transparence documentation
- Accès précoce authorisation verified against HAS decision n°2024.0128/DC/SEM of 2 May 2024
- The ASMR level granted and the negotiated CEPS prices could not be established in the public record, and are omitted rather than estimated
Frequently asked questions
Commission this model
AXLRx delivers PNH pricing strategy models built for market access and pricing teams navigating France's two-track SMR/ASMR system and accès précoce rebate mechanism. Custom model in 72 hours.
Specify your indication, market basket, and comparator scope.
AXLRx analyst confirms pricing mechanism assumptions and target population before building.
Research-verified pricing model in 72 hours with optional analyst readout.